Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SORD | Q00796 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21353591 | 0.82 | — | — | |
| SCHEMBL15800694 | 0.82 | PLD1 (0.73) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL29857922 | 0.82 | PLD1 (0.73) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL3867807 | 0.79 | KDM4E (0.64) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL29974045 | 0.77 | PLD1 (0.58) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL3258812 | 0.77 | PLD1 (0.58) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL159733 | 0.77 | PLD1 (0.61) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL29904791 | 0.77 | PLD1 (0.61) | KDM4EMAPTALDH1A1HSD17B10PLD1 | |
| SCHEMBL10053231 | 0.77 | KCNH2 (0.64) | KDM4EMAPTALDH1A1HSD17B10POLB | |
| Hydrochloric Acid SCHEMBL20337933 | 0.76 | PLD1 (0.56) | KDM4EMAPTALDH1A1HSD17B10PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | KDM4E 4873/4885MAPT 1841/4885ALDH1A1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.